Condition: PDAC · Sponsor: Anocca AB
This is an open-label, multi-centre, single-arm Phase 1/2 clinical trial of the safety, expansion, persistence and clinical activity of a set of engineered autologous T cells products each capable of recognizing a specific combination mutated KRAS and HLA, activating the T cells and exerting anti- tumour activity in patients with metastatic or locally advanced PDAC.
This description comes directly from the study's public registry record.
Amu Wang · +46703784946 · amu.wang@anocca.com
Anocca AB · +46841080701 · clinical.trials@anocca.com
Always discuss trial participation with your own doctor first.
| Herlev and Gentofte University Hospital | Copenhagen, Denmark | Recruiting |
| Charité Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
| Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus | Dresden, Germany | Recruiting |
| Universitaetsklinikum Heidelberg | Heidelberg, Germany | Recruiting |
| Universitaetsklinikum Leipzig - Universitaeren Krebszentrum (UCCL) | Leipzig, Germany | Not Yet Recruiting |
| Ludwig-Maximilians-Universitaet Muenchen (LMU) Klinikum der Universitaet Muenchen - Campus Grosshadern - Medizinische Klinik und Poliklinik III | München, Germany | Not Yet Recruiting |
| University Hospital and Faculty of Medicine Eberhard Karls University Tübingen | Tübingen, Germany | Recruiting |
| Amsterdam UMC - VU Medical Center | Amsterdam, Netherlands | Recruiting |
| Radboud University Medical Center | Nijmegen, Netherlands | Recruiting |
| Karolinska University Hospital | Stockholm, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07145450